Global Myelodysplastic Drugs Market

Myelodysplastic Drugs Comprehensive Study by Type (MDS with single lineage dysplasia, MDS with ring Sider oblasts, MDS with multilineage dysplasia's, MDS with excess blasts, Myelodysplastic syndrome associated with isolated del (5q) or with one extra chromosome change., Myelodysplastic syndrome unclassified), Application (Treat myelodysplastic syndromes by killing cells that are dividing rapidly), Therapeutic (Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics) Players and Region - Global Market Outlook to 2030

Myelodysplastic Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Myelodysplastic syndrome (MDS) is the type of cancer caused by a mutation of one or more genes that control the production of blood cells. Patients with this condition have higher-risk of acute myeloid leukemia (AML). Some of the symptoms of the MDS are breath, fatigue, easy bruising and paleness. An increasing number of patients with MDS expected to drive the demand for MDS drugs. For instance, according to the American Cancer Society every year approximately 10,000 people in the United States are diagnosed with MDS driving the demand for MSD drugs.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledCelgene (United States), Amgen (United States), Otsuka (United States), Takeda (Japan), Pfizer Inc. (United States), Eli Lilly & Company (United States), Bristol-Myers Squibb Company (United States), F. Hoffman-La Roche Ltd. (Switzerland), Becton (United States), Novartis AG (Switzerland), Ipsen Biopharmaceuticals Inc. (United States), Thermo Fisher Scientific (United States), Abbott Laboratories (United States), GE Healthcare (United States) and Agilent Technologies Inc. (United States)


This growth is primarily driven by Rise in Number of Patients with Rare Cancers and Growing Geriatric Population Myelodysplastic Syndrome (MSD) for People in their 70s.

Globally, a noticeable market trend is evident Rise in Demand of Immunomodulatory Drugs for MSD Treatment Major Players, such as Celgene (United States), Amgen (United States), Otsuka (United States), Takeda (Japan), Pfizer Inc. (United States), Eli Lilly & Company (United States), Bristol-Myers Squibb Company (United States), F. Hoffman-La Roche Ltd. (Switzerland), Becton (United States), Novartis AG (Switzerland), Ipsen Biopharmaceuticals Inc. (United States), Thermo Fisher Scientific (United States), Abbott Laboratories (United States), GE Healthcare (United States) and Agilent Technologies Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. Number of players are present in the market hence fragmented nature of the market. The increasing number of patients with cancer globally driving the demand for novel drugs and treatment. For instance, according to the World Health Organization cancer is the second leading cause of death and led to 9.6 million deaths globally in 2018. Further, growth in healthcare infrastructure in developing countries expected to generate lucrative opportunities for the companies involved in the MDS drug manufacturing.

Key Developments in the Market:

In Oct. 2023 Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced the U.S. Food and Drug Administration (FDA) has approved TIBSOVO® for the treatment of patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS).

Regulatory Insights:
“The U.S. Food and Drug Administration (FDA) has approved three medicines to treat MDS: Azacitidine (Vidaza) for both low- and high-risk patients with all sub-types of MDS, Decitabine (Dacogen) for both low- and high-risk patients with all sub-types of MDS, Lenalidomide (Revlimid) for transfusion-dependent MDS patients with isolated Del (5q) and with a low or intermediate-1 risk IPSS score.”

Influencing Trend:
Rise in Demand of Immunomodulatory Drugs for MSD Treatment and Emphasizing On Hematopoietic Stem Cell Transplantation (ASCT) Therapy for MSD

Market Growth Drivers:
Rise in Number of Patients with Rare Cancers and Growing Geriatric Population Myelodysplastic Syndrome (MSD) for People in their 70s

Challenges:
Lack of Advanced Healthcare Facilities in the Emerging Countries

Restraints:
High Cost Associated With MSD Treatment and Diagnosis

Opportunities:
Development in the Novel and Targeted Therapies Such As Immune Suppression for the Treatment of MDS and Increasing Healthcare Infrastructure in Developing Countries

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Myelodysplastic Drugs Market
- Analysis about New Entrants in Myelodysplastic Drugs Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Myelodysplastic Drugs Study Sheds Light on
— The Myelodysplastic Drugs Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Myelodysplastic Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Myelodysplastic Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • MDS with single lineage dysplasia
  • MDS with ring Sider oblasts
  • MDS with multilineage dysplasia's
  • MDS with excess blasts
  • Myelodysplastic syndrome associated with isolated del (5q) or with one extra chromosome change.
  • Myelodysplastic syndrome unclassified
By Application
  • treat myelodysplastic syndromes by killing cells that are dividing rapidly
By Therapeutic
  • Hypomethylating Agents
  • Immunomodulatory Drugs
  • Anti-anemics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Number of Patients with Rare Cancers
      • 3.2.2. Growing Geriatric Population Myelodysplastic Syndrome (MSD) for People in their 70s
    • 3.3. Market Challenges
      • 3.3.1. Lack of Advanced Healthcare Facilities in the Emerging Countries
    • 3.4. Market Trends
      • 3.4.1. Rise in Demand of Immunomodulatory Drugs for MSD Treatment
      • 3.4.2. Emphasizing On Hematopoietic Stem Cell Transplantation (ASCT) Therapy for MSD
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Myelodysplastic Drugs, by Type, Application, Therapeutic and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Myelodysplastic Drugs (Value)
      • 5.2.1. Global Myelodysplastic Drugs by: Type (Value)
        • 5.2.1.1. MDS with single lineage dysplasia
        • 5.2.1.2. MDS with ring Sider oblasts
        • 5.2.1.3. MDS with multilineage dysplasia's
        • 5.2.1.4. MDS with excess blasts
        • 5.2.1.5. Myelodysplastic syndrome associated with isolated del (5q) or with one extra chromosome change.
        • 5.2.1.6. Myelodysplastic syndrome unclassified
      • 5.2.2. Global Myelodysplastic Drugs by: Application (Value)
        • 5.2.2.1. Treat myelodysplastic syndromes by killing cells that are dividing rapidly
      • 5.2.3. Global Myelodysplastic Drugs by: Therapeutic (Value)
        • 5.2.3.1. Hypomethylating Agents
        • 5.2.3.2. Immunomodulatory Drugs
        • 5.2.3.3. Anti-anemics
      • 5.2.4. Global Myelodysplastic Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Myelodysplastic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Celgene (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Otsuka (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takeda (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly & Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol-Myers Squibb Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. F. Hoffman-La Roche Ltd. (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Becton (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Ipsen Biopharmaceuticals Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Thermo Fisher Scientific (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Abbott Laboratories (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. GE Healthcare (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Agilent Technologies Inc. (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Myelodysplastic Drugs Sale, by Type, Application, Therapeutic and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Myelodysplastic Drugs (Value)
      • 7.2.1. Global Myelodysplastic Drugs by: Type (Value)
        • 7.2.1.1. MDS with single lineage dysplasia
        • 7.2.1.2. MDS with ring Sider oblasts
        • 7.2.1.3. MDS with multilineage dysplasia's
        • 7.2.1.4. MDS with excess blasts
        • 7.2.1.5. Myelodysplastic syndrome associated with isolated del (5q) or with one extra chromosome change.
        • 7.2.1.6. Myelodysplastic syndrome unclassified
      • 7.2.2. Global Myelodysplastic Drugs by: Application (Value)
        • 7.2.2.1. Treat myelodysplastic syndromes by killing cells that are dividing rapidly
      • 7.2.3. Global Myelodysplastic Drugs by: Therapeutic (Value)
        • 7.2.3.1. Hypomethylating Agents
        • 7.2.3.2. Immunomodulatory Drugs
        • 7.2.3.3. Anti-anemics
      • 7.2.4. Global Myelodysplastic Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Myelodysplastic Drugs: by Type(USD Million)
  • Table 2. Myelodysplastic Drugs MDS with single lineage dysplasia , by Region USD Million (2018-2023)
  • Table 3. Myelodysplastic Drugs MDS with ring Sider oblasts , by Region USD Million (2018-2023)
  • Table 4. Myelodysplastic Drugs MDS with multilineage dysplasia's , by Region USD Million (2018-2023)
  • Table 5. Myelodysplastic Drugs MDS with excess blasts , by Region USD Million (2018-2023)
  • Table 6. Myelodysplastic Drugs Myelodysplastic syndrome associated with isolated del (5q) or with one extra chromosome change. , by Region USD Million (2018-2023)
  • Table 7. Myelodysplastic Drugs Myelodysplastic syndrome unclassified , by Region USD Million (2018-2023)
  • Table 8. Myelodysplastic Drugs: by Application(USD Million)
  • Table 9. Myelodysplastic Drugs Treat myelodysplastic syndromes by killing cells that are dividing rapidly , by Region USD Million (2018-2023)
  • Table 10. Myelodysplastic Drugs: by Therapeutic(USD Million)
  • Table 11. Myelodysplastic Drugs Hypomethylating Agents , by Region USD Million (2018-2023)
  • Table 12. Myelodysplastic Drugs Immunomodulatory Drugs , by Region USD Million (2018-2023)
  • Table 13. Myelodysplastic Drugs Anti-anemics , by Region USD Million (2018-2023)
  • Table 14. South America Myelodysplastic Drugs, by Country USD Million (2018-2023)
  • Table 15. South America Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 16. South America Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 17. South America Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 18. Brazil Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 19. Brazil Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 20. Brazil Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 21. Argentina Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 22. Argentina Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 23. Argentina Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 24. Rest of South America Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 27. Asia Pacific Myelodysplastic Drugs, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 31. China Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 32. China Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 33. China Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 34. Japan Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 35. Japan Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 36. Japan Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 37. India Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 38. India Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 39. India Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 40. South Korea Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 41. South Korea Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 42. South Korea Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 43. Taiwan Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 44. Taiwan Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 45. Taiwan Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 46. Australia Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 47. Australia Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 48. Australia Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 52. Europe Myelodysplastic Drugs, by Country USD Million (2018-2023)
  • Table 53. Europe Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 54. Europe Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 55. Europe Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 56. Germany Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 57. Germany Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 58. Germany Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 59. France Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 60. France Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 61. France Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 62. Italy Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 63. Italy Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 64. Italy Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 65. United Kingdom Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 68. Netherlands Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 69. Netherlands Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 70. Netherlands Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 71. Rest of Europe Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 74. MEA Myelodysplastic Drugs, by Country USD Million (2018-2023)
  • Table 75. MEA Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 76. MEA Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 77. MEA Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 78. Middle East Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 79. Middle East Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 80. Middle East Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 81. Africa Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 82. Africa Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 83. Africa Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 84. North America Myelodysplastic Drugs, by Country USD Million (2018-2023)
  • Table 85. North America Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 86. North America Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 87. North America Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 88. United States Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 89. United States Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 90. United States Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 91. Canada Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 92. Canada Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 93. Canada Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 94. Mexico Myelodysplastic Drugs, by Type USD Million (2018-2023)
  • Table 95. Mexico Myelodysplastic Drugs, by Application USD Million (2018-2023)
  • Table 96. Mexico Myelodysplastic Drugs, by Therapeutic USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Myelodysplastic Drugs: by Type(USD Million)
  • Table 113. Myelodysplastic Drugs MDS with single lineage dysplasia , by Region USD Million (2025-2030)
  • Table 114. Myelodysplastic Drugs MDS with ring Sider oblasts , by Region USD Million (2025-2030)
  • Table 115. Myelodysplastic Drugs MDS with multilineage dysplasia's , by Region USD Million (2025-2030)
  • Table 116. Myelodysplastic Drugs MDS with excess blasts , by Region USD Million (2025-2030)
  • Table 117. Myelodysplastic Drugs Myelodysplastic syndrome associated with isolated del (5q) or with one extra chromosome change. , by Region USD Million (2025-2030)
  • Table 118. Myelodysplastic Drugs Myelodysplastic syndrome unclassified , by Region USD Million (2025-2030)
  • Table 119. Myelodysplastic Drugs: by Application(USD Million)
  • Table 120. Myelodysplastic Drugs Treat myelodysplastic syndromes by killing cells that are dividing rapidly , by Region USD Million (2025-2030)
  • Table 121. Myelodysplastic Drugs: by Therapeutic(USD Million)
  • Table 122. Myelodysplastic Drugs Hypomethylating Agents , by Region USD Million (2025-2030)
  • Table 123. Myelodysplastic Drugs Immunomodulatory Drugs , by Region USD Million (2025-2030)
  • Table 124. Myelodysplastic Drugs Anti-anemics , by Region USD Million (2025-2030)
  • Table 125. South America Myelodysplastic Drugs, by Country USD Million (2025-2030)
  • Table 126. South America Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 127. South America Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 128. South America Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 129. Brazil Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 130. Brazil Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 131. Brazil Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 132. Argentina Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 133. Argentina Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 134. Argentina Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 135. Rest of South America Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 136. Rest of South America Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 137. Rest of South America Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 138. Asia Pacific Myelodysplastic Drugs, by Country USD Million (2025-2030)
  • Table 139. Asia Pacific Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 140. Asia Pacific Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 141. Asia Pacific Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 142. China Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 143. China Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 144. China Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 145. Japan Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 146. Japan Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 147. Japan Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 148. India Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 149. India Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 150. India Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 151. South Korea Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 152. South Korea Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 153. South Korea Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 154. Taiwan Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 155. Taiwan Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 156. Taiwan Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 157. Australia Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 158. Australia Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 159. Australia Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 163. Europe Myelodysplastic Drugs, by Country USD Million (2025-2030)
  • Table 164. Europe Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 165. Europe Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 166. Europe Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 167. Germany Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 168. Germany Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 169. Germany Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 170. France Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 171. France Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 172. France Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 173. Italy Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 174. Italy Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 175. Italy Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 176. United Kingdom Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 177. United Kingdom Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 178. United Kingdom Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 179. Netherlands Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 180. Netherlands Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 181. Netherlands Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 182. Rest of Europe Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 183. Rest of Europe Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 184. Rest of Europe Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 185. MEA Myelodysplastic Drugs, by Country USD Million (2025-2030)
  • Table 186. MEA Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 187. MEA Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 188. MEA Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 189. Middle East Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 190. Middle East Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 191. Middle East Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 192. Africa Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 193. Africa Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 194. Africa Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 195. North America Myelodysplastic Drugs, by Country USD Million (2025-2030)
  • Table 196. North America Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 197. North America Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 198. North America Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 199. United States Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 200. United States Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 201. United States Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 202. Canada Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 203. Canada Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 204. Canada Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 205. Mexico Myelodysplastic Drugs, by Type USD Million (2025-2030)
  • Table 206. Mexico Myelodysplastic Drugs, by Application USD Million (2025-2030)
  • Table 207. Mexico Myelodysplastic Drugs, by Therapeutic USD Million (2025-2030)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Myelodysplastic Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Myelodysplastic Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Myelodysplastic Drugs: by Therapeutic USD Million (2018-2023)
  • Figure 7. South America Myelodysplastic Drugs Share (%), by Country
  • Figure 8. Asia Pacific Myelodysplastic Drugs Share (%), by Country
  • Figure 9. Europe Myelodysplastic Drugs Share (%), by Country
  • Figure 10. MEA Myelodysplastic Drugs Share (%), by Country
  • Figure 11. North America Myelodysplastic Drugs Share (%), by Country
  • Figure 12. Global Myelodysplastic Drugs share by Players 2023 (%)
  • Figure 13. Global Myelodysplastic Drugs share by Players (Top 3) 2023(%)
  • Figure 14. Global Myelodysplastic Drugs share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 17. Celgene (United States) Revenue: by Geography 2023
  • Figure 18. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 19. Amgen (United States) Revenue: by Geography 2023
  • Figure 20. Otsuka (United States) Revenue, Net Income and Gross profit
  • Figure 21. Otsuka (United States) Revenue: by Geography 2023
  • Figure 22. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Takeda (Japan) Revenue: by Geography 2023
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Eli Lilly & Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eli Lilly & Company (United States) Revenue: by Geography 2023
  • Figure 28. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 30. F. Hoffman-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffman-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 32. Becton (United States) Revenue, Net Income and Gross profit
  • Figure 33. Becton (United States) Revenue: by Geography 2023
  • Figure 34. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 36. Ipsen Biopharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Ipsen Biopharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 39. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 40. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 41. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 42. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 43. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 44. Agilent Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 45. Agilent Technologies Inc. (United States) Revenue: by Geography 2023
  • Figure 46. Global Myelodysplastic Drugs: by Type USD Million (2025-2030)
  • Figure 47. Global Myelodysplastic Drugs: by Application USD Million (2025-2030)
  • Figure 48. Global Myelodysplastic Drugs: by Therapeutic USD Million (2025-2030)
  • Figure 49. South America Myelodysplastic Drugs Share (%), by Country
  • Figure 50. Asia Pacific Myelodysplastic Drugs Share (%), by Country
  • Figure 51. Europe Myelodysplastic Drugs Share (%), by Country
  • Figure 52. MEA Myelodysplastic Drugs Share (%), by Country
  • Figure 53. North America Myelodysplastic Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Celgene (United States)
  • Amgen (United States)
  • Otsuka (United States)
  • Takeda (Japan)
  • Pfizer Inc. (United States)
  • Eli Lilly & Company (United States)
  • Bristol-Myers Squibb Company (United States)
  • F. Hoffman-La Roche Ltd. (Switzerland)
  • Becton (United States)
  • Novartis AG (Switzerland)
  • Ipsen Biopharmaceuticals Inc. (United States)
  • Thermo Fisher Scientific (United States)
  • Abbott Laboratories (United States)
  • GE Healthcare (United States)
  • Agilent Technologies Inc. (United States)
Additional players considered in the study are as follows:
AstraZeneca (United Kingdom) , Boehringer Ingelheim (Germany) , Bayer AG (Germany) , Dickinson & Company (United States) , AbbVie, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 223 Pages 89 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Myelodysplastic Drugs Market Quantitative research analysis
Global Myelodysplastic Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Myelodysplastic Drugs market are Celgene (United States), Amgen (United States), Otsuka (United States), Takeda (Japan), Pfizer Inc. (United States), Eli Lilly & Company (United States), Bristol-Myers Squibb Company (United States), F. Hoffman-La Roche Ltd. (Switzerland), Becton (United States), Novartis AG (Switzerland), Ipsen Biopharmaceuticals Inc. (United States), Thermo Fisher Scientific (United States), Abbott Laboratories (United States), GE Healthcare (United States) and Agilent Technologies Inc. (United States), to name a few.
is dominating the Myelodysplastic Drugs Market.
"Lack of Advanced Healthcare Facilities in the Emerging Countries" is seen as one of the major challenges by many Industry Players of Myelodysplastic Drugs Market
The Myelodysplastic Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Myelodysplastic Drugs market is expected to see a steady growth rate during projected year 2023 to 2030.

Know More About Global Myelodysplastic Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Pyelonephritis Comprehensive Study by Type (Finafloxacin, Fosfomycin Tromethamine, Nacubactam, Plazomicin Sulfate), Application (Hospitals, Clinics), Treatement (Antibiotics, Hospital Admission, Surg...
$ 3500
Cerebral Palsy Treatment Comprehensive Study by Type (Medications (Musel or Nerve Injections and Oral Muscle Relaxants), Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy...
$ 3750
Premature Ejaculation Comprehensive Study by Type (Lifelong (Primary), Acquired (Secondary)), Application (Hospitals, Clinics), Treatment (Medical Therapy, Non-Medical Therapy) Players and Region - G...
$ 3500
Lyme Disease Diagnostics Comprehensive Study by Diagnostic Technology (Serological Test (ELISA, Western Blot), Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nuclei...
$ 3450
Psoriatic Arthritis Treatment Comprehensive Study by Treatment (Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others), Surgical Procedur...
$ 3750
Gene expression analysis Comprehensive Study by Type (Consumables (Reagents, DNA Chips), Instruments (PCR, NGS, Microarray)), Application (Diagnostics, Pharmacogenomics, Toxicology, Compare Expressio...
$ 3750